Refractory Diffuse Large B Cell Lymphoma
What is Refractory Diffuse Large B Cell Lymphoma (DLBCL)?
Refractory Diffuse Large B Cell Lymphoma (DLBCL) is an aggressive form of Non-Hodgkins Lymphoma (NHL). It is a type of B-Cell NHL and is the most common form of NHL in the United States. DLBCL is a rapidly growing cancer of B-cells, which are an important part of the body's immune system. It affects the lymphatic system, which helps to fight off infection and maintain body functions.
DLBCL is classified as a grade III or refractory form of the disease. This means that the cancer is more resistant to treatment than DLBCL that is not classified as refractory. Refractory DLBCL may need aggressive treatments such as chemotherapy or radiation. In some cases, stem cell transplant may be necessary.
Causes of Refractory DLBCL
The exact cause of Refractory DLBCL is unknown. However, researchers believe that certain factors such as age, genetics and HIV infection may increase the risk of developing DLBCL. People with weakened immune systems due to an HIV infection are at higher risk for developing DLBCL.
Symptoms of Refractory DLBCL
The most common symptom of Refractory DLBCL is an enlarged lymph node or lymph nodes. Other symptoms may include fatigue, fever, night sweats, weight loss, itching and enlarged spleen or liver.
Diagnosis and Treatment of Refractory DLBCL
Doctors diagnose Refractory DLBCL with a physical exam, blood tests, CT scans, bone marrow biopsy and lymph node biopsy. Treatment for Refractory DLBCL usually includes chemotherapy and radiation therapy. In severe cases, a stem cell transplant may be necessary. The prognosis of Refractory DLBCL is usually good with proper treatment and supportive care.
Preventing Refractory DLBCL
- Maintain a healthy weight.
- Exercise regularly.
- Get recommended vaccinations.
- Eat a healthy diet that includes plenty of fruits, vegetables, and whole grains.
- Avoid smoking and drinking alcohol.
- Manage any chronic medical conditions you may have.
